William Alexander

Title: Innovations in Gene Delivery by Inventor William Alexander

Introduction

William Alexander is a notable inventor based in Rockville, MD (US), recognized for his contributions to the field of gene delivery systems. He holds two patents that focus on advanced therapeutic techniques using immunoliposomes.

Latest Patents

His latest patents include the development of antibody fragment-targeted immunoliposomes for systemic gene delivery. This innovative approach utilizes cationic liposomes that are covalently conjugated with the monoclonal antibody AF-20, which specifically targets a 180 kDa cell surface glycoprotein prevalent on human hepato-cellular carcinoma (HCC) cells. The research demonstrated that these targeted liposomes significantly enhance gene expression in HuH-7 cells, achieving up to a 40-fold increase compared to control liposomes. Additionally, another patent focuses on nucleic acid-immunoliposome compositions that comprise cationic liposomes, a single chain antibody fragment binding to transferrin receptors, and nucleic acids encoding wild type p53. These compositions are designed to target cancer cells expressing transferrin receptors, offering potential therapeutic applications for various cancers.

Career Highlights

William Alexander has worked with prominent organizations such as Synergene Therapeutics, Inc. and Georgetown University. His work has significantly advanced the understanding and application of gene delivery systems in cancer treatment.

Collaborations

He has collaborated with notable colleagues, including Liang Xin Xu and Cheng-Cheng Huang, contributing to the success of his innovative projects.

Conclusion

William Alexander's work in the field of gene delivery through immunoliposomes represents a significant advancement in cancer therapy. His innovative patents and collaborations highlight his commitment to improving treatment options for patients.